euro adhoc: BB Biotech AG / Quarterly or Semiannual Financial Statements / - BB BIOTECH up 15% in first semester - convincing biotech revenues and pipeline results - dynamic growth set to continue - Board of Directors adopts measures to reduce discount (
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. The dynamic trends prevailing in the biotech industry in the first half of the year had a positive impact on BB BIOTECH and returned the company to a long-term growth path. BB BIOTECHs Net Asset ...
mehr